Liver transplantation: An update 2009

Current Opinion in Gastroenterology

Volumn 25, Issue 3, 2009, Pages 202-208

  Skagen, Catherine ^a   Lucey, Michael ^a   Said, Adnan ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b MSPH   (United States)

Author keywords

A2ALL; Downstaging; Hepatocellular carcinoma; HIV; Liver transplantation; Living donor liver transplantation; Sorafenib

Indexed keywords

AMPRENAVIR PHOSPHATE; CYCLOSPORIN; DIDANOSINE; LAMIVUDINE; NELFINAVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RAPAMYCIN; RIBAVIRIN; SORAFENIB; STAVUDINE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; GRAFT VERSUS HOST REACTION; HAND FOOT SYNDROME; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR; MITOCHONDRIAL TOXICITY; MIXED INFECTION; MORBIDITY; MORTALITY; NONHUMAN; POSTOPERATIVE COMPLICATION; RECURRENCE RISK; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 67651120260     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283299652     Document Type: Review

References (55)

1. Brown RS Jr. Live donors in liver transplantation. Gastroenterology 2008; 134:1802-1813.
2. Annual Report of the US Scientific Registry for Organ Sharing and the Organ Procurement and Transplantation Network - Transplant Data: 1988-2008. UNOS R, VA, and the Division of Transplantation, Bureau of Health Resources and Services Administration, US Department of Health and Human Services, Rockville, MD, 2008.
3. UNOS data reports [Accessed December 12].
4. http://www.nih-a2all.org/.
5. Berg CL, Gillespie BW, Merion RM, et al. Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology 2007; 133:1806-1813. Demonstrates a survival benefit with LDLT using the novel method of calculating mortality from time of first donor evaluation.
6. Freise CE, Gillespie BW, Koffron AJ, et al. Recipient morbidity after living and deceased donor liver transplantation: findings from the A2ALL retrospective cohort study. Am J Transplant 2008; 8:2569-2579. An important study of recipient outcomes with LDLT from a large multicenter study.
7. Trotter JF, Wisniewski KA, Terrault NA, et al. Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology 2007; 46:1476-1484. (Pubitemid 350155529)
8. Ghobrial RM, Freise CE, Trotter JF, et al. Donor morbidity after living donation for liver transplantation. Gastroenterology 2008; 135:468-476. A good account of donor morbidity and mortality from the largest US experience with LDLT.
9. Sevmis S, Diken T, Boyvat F, et al. Right hepatic lobe donation: impact on donor quality of life. Transplant Proc 2007; 39:826-828. (Pubitemid 46764841)
10. Erim Y, Beckmann M, Kroencke S, et al. Psychological strain in urgent indications for living donor liver transplantation. Liver Transpl 2007; 13:886-895. (Pubitemid 46939442)
11. Trotter JF, Hill-Callahan MM, Gillespie BW, et al. Severe psychiatric problems in right hepatic lobe donors for living donor liver transplantation. Transplantation 2007; 83:1506-1508. (Pubitemid 46934075)
12. Garcia-Retortillo M, Forns X, Llovet JM, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40:699-707. (Pubitemid 39265593)
13. Gaglio PJ, Malireddy S, Levitt BS, et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003; 9:1028-1035. (Pubitemid 37304457)
14. Shiffman ML, Stravitz RT, Contos MJ, et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004; 10:1248-1255. (Pubitemid 39406078)
15. Terrault NA, Shiffman ML, Lok AS, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007; 13:122-129. Good account of outcomes with LDLT for HCV that show that good outcomes are associated with center experience.
16. Lo CM, Fan ST, Liu CL, et al. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 2007; 94:78-86. (Pubitemid 46142736)
17. Fisher RA, Kulik LM, Freise CE, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007; 7:1601-1608. An important study that demonstrates worse outcomes with LDLT than DDLT for HCC. This may be related to shorter waiting time for HCC with LDLT.
18. Gondolesi GE, Roayaie S, Munoz L, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 2004; 239:142-149. (Pubitemid 38176346)
19. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004; 240:451-459. [discussion 459-461]. (Pubitemid 39121339)
20. Testa G, Malago M, Nadalin S, et al. Right-liver living donor transplantation for decompensated end-stage liver disease. Liver Transpl 2002; 8:340-346. (Pubitemid 34467367)
21. Ikegami T, Taketomi A, Soejima Y, et al. Living donor liver transplantation for acute liver failure: a 10-year experience in a single center. J Am Coll Surg 2008; 206:412-418. (Pubitemid 351282514)
22. Neff GW, Bonham A, Tzakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9:239-247. (Pubitemid 36322325)
23. Ragni MV, Belle SH, Im K, et al. Survival of human immunodeficiency virusinfected liver transplant recipients. J Infect Dis 2003; 188:1412-1420. (Pubitemid 37523925)
24. Stock PG, Roland ME, Carlson L, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003; 76:370-375. (Pubitemid 36928001)
25. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008; 8:355-365.
26. Schreibman I, Gaynor JJ, Jayaweera D, et al. Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. Transplantation 2007; 84:697-705. (Pubitemid 47480654)
27. Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20:49-57. (Pubitemid 41818114)
28. Mindikoglu AL, Regev A, Magder LS. Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database. Transplantation 2008; 85:359-368. (Pubitemid 351322759)
29. de Vera ME, Dvorchik I, Tom K, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6:2983-2993. (Pubitemid 44777929)
30. Castells L, Escartin A, Bilbao I, et al. Liver transplantation in HIV-HCV coinfected patients: a case-control study. Transplantation 2007; 83:354-358. (Pubitemid 46247870)
31. Duclos-Vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis Cafter liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47:407-417. An important study that shows worse outcomes with transplant of coinfected individuals may be related to late referral and that coinfected patients do well when transplanted at lower MELD scores.
32. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13:21-29. (Pubitemid 46099970)
33. Schwarz A, Offermann G, Keller F, et al. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation-data on four cases and review of the literature. Transplantation 1993; 55:95-103. (Pubitemid 23033953)
34. Streblow DN, Kitabwalla M, Malkovsky M, et al. Cyclophilin A modulates processing of human immunodeficiency virus type 1 p55Gag: mechanism for antiviral effects of cyclosporin A. Virology 1998; 245:197-202. (Pubitemid 28394182)
35. Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002; 109:681-688. (Pubitemid 34204847)
36. Wojcik K, Vogel M, Voigt E, et al. Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort. AIDS 2007; 21:1363-1365. (Pubitemid 46883493)
37. Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124:642-650. (Pubitemid 36268483)
38. Teicher E, Vincent I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007; 46:941-952. Important study demonstrating the interactions between calcineurin inhibitors and HAART medications.
39. Pea F, Tavio M, Pavan F, et al. Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. Antivir Ther 2008; 13:739-742.
40. Frassetto L, Baluom M, Jacobsen W, et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005; 80:13-17. (Pubitemid 40980889)
41. Terrault NA, Carter JT, Carlson L, et al. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 2006; 12:801-807.
42. MacDonald DC, Nelson M, Bower M, et al. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol 2008; 14:1657-1663.
43. Di Benedetto F, De Ruvo N, BerrettaM, et al. Hepatocellular carcinoma in HIV patients treated by liver transplantation. Eur J Surg Oncol 2008; 34:422-427.
44. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67. A good review of immunosuppression- related tumors comparing patients with HV/AIDS to transplant recipients.
45. Samuel D, Weber R, Stock P, et al. Are HIV-infected patients candidates for liver transplantation? J Hepatol 2008; 48:697-707.
46. Sherman KE, Peters M, Koziel MJ. HIV and liver disease forum: conference proceedings. Hepatology 2007; 45:1566-1577. (Pubitemid 46918341)
47. Yao FY, Hirose R, LaBerge JM, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005; 11:1505-1514. (Pubitemid 43072626)
48. Graziadei IW, Sandmueller H, Waldenberger P, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9:557-563. (Pubitemid 36701690)
49. Millonig G, Graziadei IW, Freund MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13:272-279. (Pubitemid 46351654)
50. Yao FY, Kerlan RK Jr, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48:819-827. An excellent demonstration of a successful downstaging protocol for transplantation in patients with HCC.
51. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109. (Pubitemid 39331023)
52. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390. An important study that demonstrated a survival advantage with an oral chemotherapeutic agent in advanced HCC.
53. Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 2008; 134:379. (Pubitemid 351173079)
54. Hoffmann K, GlimmH, Radeleff B, et al. Prospective, randomized, double-blind, multicenter, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation- HeiLivCa [ISRCTN24081794]. BMC Cancer 2008; 8:349.
55. Wang Z, Zhou J, Fan J, et al. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 2008; 14:5124-5130. A well designed study that demonstrated synergistic effects of an immunosuppressive agent and a chemotherapeutic agent in a xenograft model of HCC and may have implications for further similar studies in humans.